Scribe Therapeutics Inc. has announced a strategic collaboration with Prevail Therapeutics, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Personalis, Inc., National Cancer Center and Ono Pharmaceutical Co., Ltd. have announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.

Thermo Fisher Scientific has announced it is making ImmunoCAP™ Specific IgE tests available to more patients across the U.S.

Form Bio has announced the launch of FORMsightAI, a new, AI-based solution set for predicting and optimizing manufacturing outputs of cell and gene therapy constructs.

The Liquid Chromatography Flowmeter (LCF) from TESTA Analytical sets a new standard as a real-time monitoring device for continuously measuring the performance of pumps serving HPLC and uHPLC systems.

At the forefront of flow reactor design, FlowSyn™ from Uniqsis sets the standard for automated optimization of heterogeneous catalysis reactions.

Eppendorf introduces the Bioprocess Autosampler, which facilitates sampling 24/7 in short and regular intervals, gaining complete datasets.

Waters Corp introduces its newest MaxPeak Premier Oligonucleotide Columns to support applications for nucleic acid therapeutics and cell and gene therapies.

Samsara Therapeutics has announced the company’s autophagy-inducing candidate SAM001, the first agent of its class to enter clinical trials.

Gyros Protein Technologies AB has announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.